Rockville, Maryland, June 26, 2008 -- Rexahn Pharmaceuticals, Inc. (AMEX: RNN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs, today announced the publication on a bioinformatics modeling tool for drug discovery, QSID (Quantitative Structure-activity relationship tool for Innovative Discovery), in the Journal of Computer-Aided Molecular Design, DOI 10.1007/s10822-008-9219-2. The results suggest that QSID Tool is a useful modeling tool for the prediction of new analogue activities and accelerates the discovery of lead compounds.
